<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01796535</url>
  </required_header>
  <id_info>
    <org_study_id>TP201</org_study_id>
    <nct_id>NCT01796535</nct_id>
  </id_info>
  <brief_title>The PerX360º System™ Registry</brief_title>
  <acronym>OptiLIF™</acronym>
  <official_title>An Observational, Multi Center, Non-Randomized (Single Arm) Registration of the PerX360º System™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Interventional Spine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Interventional Spine, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, non-randomized post marketing surveillance registry including up to
      125 patients treated with the PerX360º System™.  Patients will receive a follow-up
      evaluation at the per physician defined time points: at discharge, an Interim 1 visit (1
      month), an Interim 2 visit (3-6 months) and a Final visit (12 months). Imaging obtained at
      visits should be per standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For all patients participating in the registry, the following outcomes will be analyzed:

        -  Change in pain score on the Visual Analog Scale(VAS) from baseline for leg pain

        -  Change in pain score on the Visual Analog Scale(VAS) from baseline for back pain

        -  Change in Oswestry Disability Index (ODI) score from baseline

        -  Proportion of patients with a device related complication

        -  Proportion of patients with lack of revision, removal, or reoperation

        -  Proportion of patients with radiographic fusion
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only</study_design>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Fusion</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Image Assessment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>DDD</condition>
  <arm_group>
    <arm_group_label>PerX360º System™</arm_group_label>
    <description>Patients treated with PerX360º System™</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects treated with the Optiport™ and Opticage™ products
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient understands the nature of the procedure and provides written informed consent

          -  Patient is willing to return to the treating physician for his/her routine follow-up
             visits up to 12 months post treatment

          -  Age &gt; 18 years

          -  Patient is treated with the Optiport™ and Opticage™ products

        Exclusion Criteria:None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Butler</last_name>
    <phone>858 220 6904</phone>
    <email>mbutler@i-spineinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Los Angeles Brain and Spine Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Rappard</last_name>
      <phone>323-857-5300</phone>
      <phone_ext>202</phone_ext>
      <email>rappardnancy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Rappard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flagler Hospital</name>
      <address>
        <city>St. Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Greenwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 13, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
